Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

AUA: Studies Highlight Links Between Bladder Cancer, E-Cigarettes

May 15, 2017
By Dave Levitan
Article

New studies at the AUA Annual Meeting highlight the links between smoking and bladder cancer. In one, smoking intensity was linked to survival outcomes, while two others show that electronic cigarettes likely contribute to bladder cancer risk.

Several new studies presented at the Annual Scientific meeting of the American Urological Association (AUA) highlight the important links between smoking and bladder cancer. In one, smoking intensity was linked to survival outcomes in bladder cancer patients, while two others show that electronic cigarettes likely contribute to bladder cancer risk.

“This research underscores the importance of smoking cessation (of both traditional and e-cigarettes) for people with bladder cancer, and people looking to avoid it,” said Sam S. Chang, MD, MBA, of Vanderbilt–Ingram Cancer Center in Nashville, who moderated the session with the new studies, in a press release.

The first study, led by Luis Felipe Sávio, MD, of the University of Miami Miller School of Medicine in Florida, used the Florida Cancer Data System to identify 14,077 bladder cancer patients who smoked. Of those, 25% smoked less than one pack of cigarettes per day, 63% smoked between one and two packs per day, and 12% smoked more than two packs per day.

The median overall survival (OS) for the full cohort was 4 years, and the 5-year OS rate was 43.7%. For those who smoked less than one, one to two, and more than two packs per day, the median OS was 4.2 years, 3.9 years, and 4.1 years, respectively; 5-year OS rates for these groups were 45.1%, 43.1%, and 43.6%, respectively. Using the group that smoked less than one pack as a reference, those smoking one to two packs daily had a hazard ratio (HR) for mortality of 1.11 (95% CI, 1.06–1.16; P < .001); for more than two packs per day, the HR was 1.08 (95% CI, 1.00–1.16; P = .042).

The other studies focused on e-cigarettes. Thomas Fuller, MD, of the University of Pittsburgh, led a study that compared the urine of 13 e-cigarette users to 10 non-smokers, analyzing them for five known bladder carcinogens: benz(a)anthracene, benzo(a)pyrene, 1-hydroxypyrene, o-toluidine, and 2-naphthylamine.

Two of those five molecules-o-toluidine and 2-naphthylamine-were found in urine of 12 of the 13 e-cigarette users. They were found in none of the control participants, and the other three carcinogens were not found in any of the participants.

In the other study, led by Hyun-Wook Lee, PhD, of New York University School of Medicine, researchers using a mouse model found that e-cigarette smoke can induce tumorigenic DNA damage in bladder mucosa. This was also seen in an in vitro experiment using human urothelial cells.

“These studies raise new concerns about the harmful impact of e-cigarettes on bladder cancer,” Chang said. “We’ve known traditional smoking raises bladder cancer risk, and given the surge in popularity of e-cigarettes, it’s imperative we uncover any potential links to e-cigarette smoke and bladder cancer.”

Recent Videos
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Related Content
Advertisement

The 2-year rates for disease-free survival in the radiation and observation arms, respectively, were 71.6% vs 58.7%.

Adjuvant Radiation Therapy Improves Local Survival in High-Risk MIBC

Roman Fabbricatore
September 29th 2025
Article

No toxicity-related discontinuations were seen with adjuvant radiotherapy among patients with muscle-invasive bladder cancer.


Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.


How Will Gemcitabine Intravesical System Impact BCG-Unresponsive NMIBC?

How Will Gemcitabine Intravesical System Impact BCG-Unresponsive NMIBC?

Ariana Pelosci
September 16th 2025
Article

Gary Steinberg, MD, highlights the FDA approval of the gemcitabine intravesical system and what this means for patients with BCG-unresponsive NMIBC.


Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 14th 2025
Podcast

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.


Patients with muscle-invasive bladder cancer with a positive Signatera test displayed a significant improvement in disease-free and overall survival.

ctDNA Test is Predictive of Adjuvant Atezolizumab Benefit in MIBC

Roman Fabbricatore
August 18th 2025
Article

Patients with muscle-invasive bladder cancer with a positive Signatera test displayed a significant improvement in disease-free and overall survival.


In July 2025, the FDA granted priority review to TAR-200 in patients with BCG-unresponsive high-risk NMIBC.3

TAR-200 Appears Highly Efficacious, Safe in BCG-Unresponsive NMIBC

Tim Cortese
August 15th 2025
Article

Results from the SunRISe-1 trial showed that TAR-200 monotherapy achieved a complete response rate of 82.4% in patients with BCG-unresponsive NMIBC.

Related Content
Advertisement

The 2-year rates for disease-free survival in the radiation and observation arms, respectively, were 71.6% vs 58.7%.

Adjuvant Radiation Therapy Improves Local Survival in High-Risk MIBC

Roman Fabbricatore
September 29th 2025
Article

No toxicity-related discontinuations were seen with adjuvant radiotherapy among patients with muscle-invasive bladder cancer.


Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.


How Will Gemcitabine Intravesical System Impact BCG-Unresponsive NMIBC?

How Will Gemcitabine Intravesical System Impact BCG-Unresponsive NMIBC?

Ariana Pelosci
September 16th 2025
Article

Gary Steinberg, MD, highlights the FDA approval of the gemcitabine intravesical system and what this means for patients with BCG-unresponsive NMIBC.


Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 14th 2025
Podcast

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.


Patients with muscle-invasive bladder cancer with a positive Signatera test displayed a significant improvement in disease-free and overall survival.

ctDNA Test is Predictive of Adjuvant Atezolizumab Benefit in MIBC

Roman Fabbricatore
August 18th 2025
Article

Patients with muscle-invasive bladder cancer with a positive Signatera test displayed a significant improvement in disease-free and overall survival.


In July 2025, the FDA granted priority review to TAR-200 in patients with BCG-unresponsive high-risk NMIBC.3

TAR-200 Appears Highly Efficacious, Safe in BCG-Unresponsive NMIBC

Tim Cortese
August 15th 2025
Article

Results from the SunRISe-1 trial showed that TAR-200 monotherapy achieved a complete response rate of 82.4% in patients with BCG-unresponsive NMIBC.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.